-
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002
Capricor Therapeutics has announced positive 3-year results from the ongoing HOPE-2 open-label extension (OLE) study […]
-
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Read the full news release HERE Capricor Therapeutics, which received early funding from CureDuchenne, has […]
-
What’s it like to have three sons living with DMD?
What’s it like to have three children with Duchenne muscular dystrophy (DMD)? That’s the question […]
-
I tried home health physical therapy, but will I keep exercising?
In a column I wrote last month, I talked about finally deciding to try some […]
-
Engineered tRNA fixes faulty dystrophin protein in DMD mice
An engineered transfer RNA (tRNA) molecule developed by hC Bioscience could be a fix for […]
-
What I take away from watching the filmed version of ‘Hamilton’
Last week, my girlfriend and I caught the 2020 filmed version of Lin-Manuel Miranda’s award-winning […]
-
Viltepso fails main goal in confirmatory Phase 3 study
After nearly a year of treatment, Viltepso (viltolarsen) was well tolerated and tended to increase […]
-
NS Pharma Shares Update on VILTEPSO® (Viltolarsen) Phase 3 Study
NS Pharma, Inc. has shared preliminary analysis results from RACER53, the global Phase 3 clinical […]
-
Meeting of the Minds 2024
As we prepare to welcome families to the CureDuchenne FUTURES Annual Conference, scientific leaders, executives […]
-
Our son’s graduation from high school was beautifully exhausting
My oldest son, Max, 18, graduated from high school last Sunday. Graduation is a milestone […]
